| diagnosis |
159 |
| management |
159 |
| psoratic arthritis |
159 |
| treatment |
159 |
| belimumab |
172 |
| clinical improvement |
172 |
| early effectiveness |
172 |
| prednisone |
172 |
| safety |
172 |
| systemic lupus erythematosus |
172 |
| assessment |
180 |
| hip osteoarthritis |
180 |
| outcome |
180 |
| reliability |
180, 294 |
| validity |
180, 294 |
| antineutrophil cytoplasmic antibody-associated vasculitis |
194 |
| classification criteria |
194 |
| eosinophilic granulomatosis with polyangiitis |
194 |
| granulomatosis with polyangiitis |
194 |
| microscopic polyangiitis |
194 |
| disease-modifying antirheumatic drugs |
203 |
| hospitalization |
203 |
| mortality rate |
203 |
| rheumatic diseases |
203 |
| severe acute respiratory syndrome coronavirus 2 |
203 |
| idiopathic inflammatory myopathy |
213 |
| interstitial lung disease |
213 |
| pulmonary infection |
213 |
| risk factors |
213 |
| child |
221 |
| covid-19 |
221 |
| rheumatic disease |
221 |
| vaccination |
221 |
| adverse event |
232 |
| ankylosing spondylitis |
232 |
| biological disease-modifying anti-rheumatic drug |
232 |
| geriatric |
232 |
| tumor necrosis factor inhibitor |
232 |
| disease activity |
242 |
| enthesitis |
242 |
| spondyloarthritis |
242 |
| ultrasonography |
242 |
| pediatric rheumatology |
255 |
| transition care |
255 |
| transition-q |
255 |
| starx |
255 |
| diagnostic value |
265 |
| gouty arthritis |
265 |
| musculoskeletal ultrasound |
265 |
| serum uric acid |
265 |
| auto-antibodies |
274 |
| early rheumatoid arthritis |
274 |
| rheumatoid arthritis |
274, 303 |
| risk factor |
274 |
| small joint |
274 |
| axial spondyloarthritis |
285 |
| elafin |
285 |
| secretory leukocyte protease inhibitor |
285 |
| cognitive function |
294 |
| fibromyalgia |
294 |
| questionnaire |
294 |
| layer specific global longitudinal strain |
303 |
| speckle tracking echocardiography |
303 |
| anti-cd20 |
317 |
| meta-analysis |
317 |
| rheumatoid arthritis-related interstitial lung disease |
317 |
| rituximab |
317 |
